Scaling Patient-Derived CAR‑T Therapy Requires Thousands of Separate Manufacturing Cycles

Scaling Patient-Derived CAR‑T Therapy Requires Thousands of Separate Manufacturing Cycles

On September 1, PharmaVoice described the manufacturing challenge of autologous CAR‑T therapy: each patient needs a separate process from cell collection through treatment. Using Carvykti as an example, the article shows how this process depends on manufacturing, quality control, logistics, and clinical scheduling.

Autologous CAR‑T is a cell therapy for cancer made from the patient’s own cells. Clinicians collect the patient’s T‑cells, which are immune cells. In the laboratory, the cells are engineered to express a receptor that recognizes the tumor, expanded, tested, and returned to the same patient. Each dose goes through a separate manufacturing cycle.

As the number of patients grows, clinics and manufacturers must manage more of these cycles at the same time. The cells, an available manufacturing slot, materials, quality control, dose release, delivery, and treatment schedule must all align on time for each individual patient. A delay at any stage postpones treatment for that specific patient.

Mike O’Mara, chief operating officer of Cellipont Bioservices, a contract manufacturer of cell therapies, explained: “When you scale autologous cell therapy, you are not expanding a single batch. You are replicating processes.”

At an early stage, one experienced team can complete several such cycles. In commercial manufacturing, several teams carry out the same individualized process simultaneously. Manual steps and differences between operators therefore have a greater effect on quality and timing. Automation and closed processing systems reduce both the number of manual steps and the variation between cycles.

The Carvykti network already illustrates this scale. According to Legend Biotech, the treatment is available at 348 sites in 19 countries, and all four of its manufacturing sites are operational. The company states that its expanded facility in Raritan, New Jersey, has capacity to treat up to 10 000 patients per year. Even at that capacity, every individualized dose must undergo quality control and release, reach its destination, and fit into the treatment center’s schedule.

In June 2025, the FDA eliminated the dedicated REMS safety program for six approved autologous CAR‑T therapies, including Carvykti. The agency removed the separate certification requirement for treatment centers and updated the instructions for monitoring patients after administration. Eliminating REMS simplified part of the process that follows dose release.

With in vivo CAR‑T, a genetic vector that carries instructions for cells modifies immune cells directly inside the patient’s body. In June, the first phase I data for LB2501 confirmed that this approach is already being tested in humans. The ongoing phase I study of LB2501 is assessing whether a single infusion can generate CAR‑T cells inside the body. This approach could shift much of the external cell processing to a standardized vector product that can be used for many patients. The vector product must still be manufactured reliably at commercial scale.

#clinical_trials